An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

  • End date
    Jul 22, 2025
  • participants needed
  • sponsor
    GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Updated on 22 October 2022


This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.

Condition Pulmonary Arterial Hypertension
Treatment Generic Dry Powder Inhaler, GB002 (seralutinib)
Clinical Study IdentifierNCT04816604
SponsorGB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Last Modified on22 October 2022


Yes No Not Sure

Inclusion Criteria

Type of Subject and Disease Characteristics
Subjects must have completed a prior GB002 PAH study and, in the opinion of the Investigator and Sponsor, have been compliant with study procedures and have completed treatment with IP through parent study end-of-treatment (EOT) visit
Treatment with standard of care PAH disease-specific background therapies (stable dose)
Informed Consent
Review and signature of an IRB-approved informed consent form

Exclusion Criteria

Medical Conditions
Persistent and clinically significant systemic hypertension or hypotension
Interval history of newly developed left-sided heart disease
Potentially life-threatening cardiac arrhythmia with an ongoing risk
Uncontrolled bacterial, viral, or fungal infections which require systemic therapy
Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or GB002 administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study
History of portopulmonary hypertension or portal hypertension due to cirrhosis classified as Child-Pugh Class A or higher
Subjects with a history of severe milk protein allergy. In addition, subjects with known intolerance or hypersensitivity to lactose who, in the opinion of the investigator, may experience severe symptoms following the ingestion of lactose
Current use of inhaled tobacco and/or inhaled marijuana. Ingestible or topical marijuana is allowed, per local restrictions and regulations
Current alcohol use disorder as defined by DSM-5, and/or history of current utilization of drugs of abuse (amphetamines, methamphetamines, cocaine, phencyclidine [PCP])
Have any other condition or reason that, in the opinion of the Investigator and/or the Sponsor's Medical Monitor (or designee), would prohibit the subject from participating in the study
Diagnostic Assessments
Chronic renal insufficiency
Hemoglobin (Hgb) concentration <8.5 g/dL
Absolute neutrophil count (ANC) < 1x 10^9/L
Platelet count <50 x 10^9/L
Prior Therapy
Use of inhaled prostanoids
Chronic use of oral anticoagulants (ie, vitamin K antagonist such as warfarin or novel oral anticoagulant [NOAC]/direct oral anticoagulant [DOAC])
Chronic use of any prohibited medication
NOTE: Additional inclusion/exclusion criteria may apply, per protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note